The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer

PurposeSince the introduction of positron emission tomography (PET) imaging with 68Ga-PSMA-HBED-CC (=68Ga-DKFZ-PSMA-11), this method has been regarded as a significant step forward in the diagnosis of recurrent prostate cancer (PCa). However, published data exist for small patient cohorts only. The aim of this evaluation was to analyse the diagnostic value of 68Ga-PSMA-ligand PET/CT in a large cohort and the influence of several possibly interacting variables.MethodsWe performed a retrospective analysis in 319 patients who underwent 68Ga-PSMA-ligand PET/CT from 2011 to 2014. Potential influences of several factors such as prostate-specific antigen (PSA) level and doubling time (DT), Gleason score (GSC), androgen deprivation therapy (ADT), age and amount of injected tracer were evaluated. Histological verification was performed in 42 patients after the 68Ga-PSMA-ligand PET/CT. Tracer uptake was measured in 901 representative tumour lesions.ResultsIn 82.8 % of the patients at least one lesion indicative of PCa was detected. Tumor-detection was positively associated with PSA level and ADT. GSC and PSA-DT were not associated with tumor-detection. The average maximum standardized uptake value (SUVmax) of tumour lesions was 13.3 ± 14.6 (0.7–122.5). Amongst lesions investigated by histology, 30 were false-negative in 4 different patients, and all other lesions (n = 416) were true-positive or true-negative. A lesion-based analysis of sensitivity, specificity, negative predictive value (NPV) and positive predictive value (PPV) revealed values of 76.6 %, 100 %, 91.4 % and 100 %. A patient-based analysis revealed a sensitivity of 88.1 %. Of 116 patients available for follow-up, 50 received local therapy after 68Ga-PSMA-ligand PET/CT.Conclusion68Ga-PSMA-ligand PET/CT can detect recurrent PCa in a high number of patients. In addition, the radiotracer is highly specific for PCa. Tumour detection is positively associated with PSA and ADT. 68Ga-PSMA-ligand PET/CT can help delay systemic therapy of PCa.

[1]  Z. Hall.  Cancer , 1906, The Hospital.

[2]  M. Resnick.  Hormonal therapy in prostatic carcinoma. , 1984, Urology.

[3]  M. Orgel,et al.  Management of penile incarceration. , 1984, Urology.

[4]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[5]  P. Schellhammer,et al.  Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. , 1996, Urology.

[6]  C. Cordon-Cardo,et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  N. Bander,et al.  Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. , 1997, Cancer research.

[8]  D. Bostwick,et al.  Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. , 1998, Urology.

[9]  S. Fosså,et al.  Computed tomography/magnetic resonance based volume changes of the primary tumour in patients with prostate cancer with or without androgen deprivation. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  Prabhjot Kaur,et al.  Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  J. Quian,et al.  Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. , 2004, Histology and histopathology.

[12]  M Bolla,et al.  EAU guidelines on prostate cancer. , 2001, European urology.

[13]  G. V. von Schulthess,et al.  Fluorocholine PET/CT in patients with prostate cancer: initial experience. , 2005, Radiology.

[14]  W. Sega,et al.  Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. , 2006, The Journal of urology.

[15]  N. Bander.  Technology Insight: monoclonal antibody imaging of prostate cancer , 2006, Nature Clinical Practice Urology.

[16]  R. Miralbell,et al.  Evaluation of [18F]-choline PET/CT for staging and restaging of prostate cancer , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  S. Kohlfuerst,et al.  The value of 18F-Choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  Prostate biopsy guided by 18F-fluorocholine PET in men with persistently elevated PSA levels , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  Slave Trajanoski,et al.  Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis , 2009, Pathology & Oncology Research.

[20]  Michel Bolla,et al.  [EAU guidelines on prostate cancer]. , 2009, Actas urologicas espanolas.

[21]  Martin G Pomper,et al.  Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. , 2009, Cancer research.

[22]  H. VanBrocklin,et al.  Assessment of an 18F-Labeled Phosphoramidate Peptidomimetic as a New Prostate-Specific Membrane Antigen–Targeted Imaging Agent for Prostate Cancer , 2009, Journal of Nuclear Medicine.

[23]  S. Larson,et al.  89Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In Vivo , 2010, The Journal of Nuclear Medicine.

[24]  S. Larson,et al.  Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen , 2011, Proceedings of the National Academy of Sciences.

[25]  M. Pomper,et al.  2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer , 2011, Clinical Cancer Research.

[26]  A. Haese*,et al.  High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancer , 2011, The Prostate.

[27]  U. Haberkorn,et al.  [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  U. Haberkorn,et al.  68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. , 2012, Bioconjugate chemistry.

[29]  T. Holland-Letz,et al.  PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[30]  U. Haberkorn,et al.  A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer , 2012, EJNMMI Research.

[31]  J. Osborne,et al.  Review of Salvage Therapy for Biochemically Recurrent Prostate Cancer: The Role of Imaging and Rationale for Systemic Salvage Targeted Anti-Prostate-Specific Membrane Antigen Radioimmunotherapy , 2012, Advances in urology.

[32]  Tiancheng Liu,et al.  Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells , 2012, International journal of oncology.

[33]  M. Roethke,et al.  PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[34]  T. Holland-Letz,et al.  Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[35]  M. Loda,et al.  Prostate-Specific Membrane Antigen Protein Expression in Tumor Tissue and Risk of Lethal Prostate Cancer , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[36]  M. Roethke,et al.  Hybrid positron emission tomography-magnetic resonance imaging with gallium 68 prostate-specific membrane antigen tracer: a next step for imaging of recurrent prostate cancer-preliminary results. , 2013, European urology.

[37]  U. Haberkorn,et al.  PSMA as a target for radiolabelled small molecules , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[38]  A. Kopp-Schneider,et al.  Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[39]  B. Hadaschik,et al.  Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[40]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[41]  B. Hadaschik,et al.  I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy , 2014 .